Journal of Organometallic Chemistry p. 89 - 96 (2017)
Update date:2022-08-11
Topics:
Iftikhar, Tuba
Rauf, Muhammad Khawar
Sarwar, Sidra
Badshah, Amin
Waseem, Durdana
Tahir, Muhammad Nawaz
Khan, Amjad
Khan, Khalid Mohammad
Khan, Gul Majid
Antimony (V) organometallics (1–5) have been synthesized with general formula [SbR′3(O2CR)2], where R' = phenyl, p-tolyl and O2CR are substituted cinnamates. These complexes have been characterized by FT-IR analysis, multinuclear (1H, 13C) NMR spectroscopy and single crystal X-ray diffraction analysis. The crystal structures of [Sb(phenyl)3(4-ClC6H4C2H2O2C)2] (1) and [Sb(p-tol)3(4-OCH3C6H4C2H2O2C)2].CHCl3 (5) displayed distorted geometry between trigonal bipyramidal and square pyramidal with monomeric structure at a five coordinated Sb center. Starting reagents and complexes were evaluated for anticancer, antileishmanial, antibacterial and alpha amylase inhibition potentials. It was observed that complexes 3, 4 and 5 showed significant (p < 0.05) antileishmanial and anticancer activities against Leishmania tropica KWH23 promastigotes and HepG2 cell lines respectively. Antibacterial activity of compound 3 was also significant against E. coli (MIC: 5.55 μg/mL), K. pneumoniae (MIC: 16.66 μg/mL), S. aureus (MIC: 5.55 μg/mL) and P. aeruginosa (MIC: 50 μg/mL). Hence, these new antimony complexes can act as good drug candidates.
View MoreJiangxi Dongbang Pharmaceutical Co., Ltd.
Contact:+86-795-4433603, 4433388
Address:Fengxin Industrial Park, Fengxin County, Jiangxi Province, P.R.C
Cangzhou Senary Chemical Science-tech Co., Ltd
Contact:+86-317-3563899, 3563699
Address:168 Jinde Road, Cangzhou, Hebei, China
Jewim Pharmaceutical (Shandong) Co., Ltd
Contact:+8615621883869
Address:山东省泰安市高新技术产业开发区配天门大街西首
Yixing Bluwat Chemicals Co., Ltd.
Contact:+86 510 87821568
Address:Yongan Road, Yixing Chemical Industrial Park, Yixing, Jiangsu, China
Shanghai Boyners Pharmaceutical co., LTD.
Contact:+86-02131329586/02154581719
Address:No.328,1#315,Wuhe Road, Shanghai, ,shanghai,China (Mainland)
Doi:10.1007/BF00771505
()Doi:10.1021/j100321a060
(1988)Doi:10.1016/j.jallcom.2014.06.016
(2014)Doi:10.1002/ejic.202000971
(2021)Doi:10.1007/s11172-020-2965-6
(2020)Doi:10.1002/anie.201803848
(2018)